This company has been marked as potentially delisted and may not be actively trading. FS Development (FSDC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock FSDC vs. MOR, GMTX, CALT, ZYME, SBTX, MBX, AVTE, PTN, NLTX, and CYBNShould you be buying FS Development stock or one of its competitors? The main competitors of FS Development include MorphoSys (MOR), Gemini Therapeutics (GMTX), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Silverback Therapeutics (SBTX), MBX Biosciences (MBX), Aerovate Therapeutics (AVTE), Palatin Technologies (PTN), Neoleukin Therapeutics (NLTX), and Cybin (CYBN). FS Development vs. Its Competitors MorphoSys Gemini Therapeutics Calliditas Therapeutics AB (publ) Zymeworks Silverback Therapeutics MBX Biosciences Aerovate Therapeutics Palatin Technologies Neoleukin Therapeutics Cybin FS Development (NASDAQ:FSDC) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability. Is FSDC or MOR more profitable? FS Development has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. FS Development's return on equity of 0.00% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets FS DevelopmentN/A N/A N/A MorphoSys -226.79%-694.31%-22.55% Which has better earnings & valuation, FSDC or MOR? FS Development has higher earnings, but lower revenue than MorphoSys. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFS DevelopmentN/AN/AN/AN/AN/AMorphoSys$238.28M11.99-$205.35M-$3.48-5.45 Does the media prefer FSDC or MOR? In the previous week, FS Development's average media sentiment score of 0.00 equaled MorphoSys'average media sentiment score. Company Overall Sentiment FS Development Neutral MorphoSys Neutral Do institutionals and insiders believe in FSDC or MOR? 89.8% of FS Development shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 0.1% of MorphoSys shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryFS Development beats MorphoSys on 4 of the 6 factors compared between the two stocks. Get FS Development News Delivered to You Automatically Sign up to receive the latest news and ratings for FSDC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FSDC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FSDC vs. The Competition Export to ExcelMetricFS DevelopmentPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$743.58M$853.52M$5.73B$9.76BDividend YieldN/A4.84%4.40%4.08%P/E RatioN/A1.1530.3826.03Price / SalesN/A26.26428.56103.94Price / CashN/A19.5625.7828.79Price / BookN/A6.779.706.08Net IncomeN/A-$4.17M$3.27B$265.64M FS Development Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FSDCFS DevelopmentN/A$59.41-1.6%N/A+22.1%$743.58MN/A0.00N/AMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730Positive NewsGMTXGemini TherapeuticsN/A$59.03+0.8%N/A+22.1%$2.56BN/A-59.0330CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ZYMEZymeworks1.3617 of 5 stars$13.94+7.1%$21.43+53.7%+27.9%$1.05B$122.87M-9.29460SBTXSilverback TherapeuticsN/A$16.66+1.7%N/A+4.2%$600.73MN/A-6.8883Positive NewsHigh Trading VolumeMBXMBX Biosciences1.9246 of 5 stars$12.95+3.4%$37.63+190.5%N/A$435.04MN/A-2.8536News CoverageAVTEAerovate TherapeuticsN/A$7.39-0.1%N/A-87.4%$214.20MN/A-2.4720High Trading VolumePTNPalatin TechnologiesN/A$7.20+7,551.4%N/AN/A$187.24M$350K-4.6530Gap UpNLTXNeoleukin TherapeuticsN/A$19.22-5.6%N/A-42.8%$180.63MN/A-6.1890High Trading VolumeCYBNCybin2.3866 of 5 stars$7.60-0.4%$85.00+1,018.4%N/A$179.28MN/A-1.7350News Coverage Related Companies and Tools Related Companies MorphoSys Competitors Gemini Therapeutics Competitors Calliditas Therapeutics AB (publ) Competitors Zymeworks Competitors Silverback Therapeutics Competitors MBX Biosciences Competitors Aerovate Therapeutics Competitors Palatin Technologies Competitors Neoleukin Therapeutics Competitors Cybin Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FSDC) was last updated on 8/26/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s national nightmare is hereWhile the headlines focus on global conflicts, there’s a very different crisis brewing at home. Washington has...Porter & Company | SponsoredIt’s game over for Central BanksCentral banks are losing control. Inflation isn’t fixed, debt is exploding, and stocks have never looked more ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FS Development Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share FS Development With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access